Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 01/04/2024 at 07:00, 2 years 5 months ago

Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com

Biophytis COVA Phase 2-3 Study Sarconeos (BIO101) Publication Severe COVID-19 Treatment Respiratory Viral Infections Clinical Benefits Of Sarconeos (BIO101)
ARTICLE

published on 12/29/2023 at 07:59, 2 years 5 months ago

Biophytis avance dans son financement avec l'émission de la quatrième tranche d'ORNANE
Biophytis annonce le tirage de la quatrième tranche d'ORNANE auprès du fonds d’investissement Atlas sous le cadre du contrat de financement conclu en 2021

Biophytis Financement ORNANE Atlas Médicament
PRESS RELEASE

published on 12/29/2023 at 07:00, 2 years 5 months ago

Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021
Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021. La société de biotechnologie au stade clinique spécialisée dans le développement de traitements qui visent à ralentir les processus dégénératifs liés au vieillissement va émettre 80 ORNANE pour un montant de 2 millions d’euros, avec une option complémentaire de 80 ORNANE pour un montant de 2 millions d’euros le 15 février 2024

Biophytis ORNANE Atlas 2021 Fonds D'investissement Obligations Remboursables
PRESS RELEASE

published on 12/29/2023 at 07:00, 2 years 5 months ago

Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract
Biophytis, a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases, has announced the drawing of the fourth tranche of its convertible bond agreement with Atlas, a specialized investment fund based in New York. This tranche consists of 80 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with a total value of €4 million. The ORNANE have a 24-month maturity period and do not bear interest. Holders have the option
ARTICLE

published on 12/11/2023 at 07:49, 2 years 6 months ago

Biophytis présente son calendrier de conférences internationales pour le premier trimestre 2024
Biophytis SA confirme sa présence dans des conférences clés du secteur de la santé, visant à renforcer ses relations et à présenter ses avancées

Biophytis Biotechnologie Sarconeos (BIO101) Conférences Traitements Anti-vieillissement
ARTICLE

published on 12/04/2023 at 08:00, 2 years 6 months ago

Biophytis et l'Université de Liège s'associent pour combattre l'insuffisance respiratoire virale
Biophytis annonce un partenariat avec l'Université de Liège pour étudier Sarconeos (BIO101) dans le traitement de pathologies respiratoires

Biophytis Université De Liège Insuffisance Respiratoire Recherche Préclinique Médicament Sarconeos
PRESS RELEASE

published on 11/27/2023 at 07:00, 2 years 6 months ago

Biophytis nomme Yann Meunier et Bernard Lévy à son comité scientifique
PRESS RELEASE

published on 11/20/2023 at 07:00, 2 years 7 months ago

Biophytis annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription pour un montant d’environ 1,96 M€
PRESS RELEASE

published on 11/17/2023 at 23:00, 2 years 7 months ago

Biophytis reçoit une notification du Nasdaq
PRESS RELEASE

published on 11/06/2023 at 07:00, 2 years 7 months ago

Biophytis to attend BIO-Europe in Munich

Published on 06/23/2026 at 14:30, 23 minutes ago

AIAI Holdings Unveils AI Integration Playbook for Portfolio Companies
Published on 06/23/2026 at 14:30, 23 minutes ago

Sekur Private Data Appoints Former U.S. State Department Deputy Assistant Secretary Annette L. Redmond to its Strategic Advisory Board
Published on 06/23/2026 at 14:00, 53 minutes ago

Hillcrest Energy Technologies Receives Letter of Intent from Lenze SE to Advance ZVS Technology Evaluation
Published on 06/23/2026 at 14:00, 53 minutes ago

Datametrex Announces Rebranding of Paymetrex to QuantIP Licensing Corp.
Published on 06/23/2026 at 14:00, 53 minutes ago

Tectonic Metals Inc. Approves Advance Notice Policy

View all ACCESSWIRE

Published on 06/23/2026 at 14:20, 33 minutes ago

Zafin Launches AIOS, an End-to-End Platform to Orchestrate and Govern Agentic Work
Published on 06/23/2026 at 14:08, 45 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 06/23/2026 at 14:07, 46 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 06/23/2026 at 14:06, 47 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Forward Industries Inc.
Published on 06/23/2026 at 14:06, 47 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc

View all EQS

Published on 06/23/2026 at 14:00, 53 minutes ago

Neoen remporte un contrat long terme pour une nouvelle batterie de 200 MW / 8 heures en Ontario
Published on 06/23/2026 at 14:00, 53 minutes ago

Neoen awarded long-term contract for new 200 MW / 8-hour battery in Ontario, Canada
Published on 06/22/2026 at 18:45, 20 hours 8 minutes ago

Governance evolution
Published on 06/22/2026 at 18:45, 20 hours 8 minutes ago

ÉVOLUTION DE LA GOUVERNANCE
Published on 06/22/2026 at 18:16, 20 hours 37 minutes ago

ANTOINE FREY INCREASES HIS STAKE IN FREY

View all LES ECHOS COMFI WIRE

News